熊去氧胆酸胶囊联合糖皮质激素对自身免疫性肝炎患者肝纤维化指标及免疫功能的影响  

Impact of Ursodeoxycholic Acid Capsules Combined with Glucocorticoids on Liver Fibrosis Indicators and Immune Function in Patients with Autoimmune Hepatitis

作　　者：魏晓婷[1] 马洪德[1] WEI Xiaoting;MA Hongde(Department of Infection,Pingdingshan First People's Hospital,Pingdingshan 467000,China)

机构地区：[1]平顶山市第一人民医院感染科,河南平顶山467000

出　　处：《临床医学工程》2024年第5期597-598,共2页Clinical Medicine & Engineering

摘　　要：目的探讨分析熊去氧胆酸胶囊联合糖皮质激素对自身免疫性肝炎(AIH)患者肝纤维化指标及免疫功能的影响。方法选取2022年1月至2023年1月我院收治的AIH患者84例,随机分为两组各42例。对照组采用糖皮质激素治疗,观察组在对照组基础上采用熊去氧胆酸胶囊治疗,两组均治疗6个月。比较两组的临床效果、肝纤维化指标、免疫功能以及不良反应。结果观察组治疗总有效率高于对照组(P<0.05)。治疗后,观察组肝纤维化指标及免疫功能指标均低于对照组(P<0.05)。两组患者治疗过程中均未出现明显不良反应。结论熊去氧胆酸胶囊联合糖皮质激素治疗AIH患者的效果显著,可改善患者肝纤维化指标,促进肝功能恢复,并增强免疫功能,临床应用安全性高。Objective To analyze the impact of ursodeoxycholic acid capsules combined with glucocorticoids on liver fibrosis and immune function in patients with autoimmune hepatitis(AIH).Methods 84 AIH patients admitted to our hospital from January 2022 to January 2023 were selected and randomly divided into two groups,with 42 cases in each group.The control group was treated with glucocorticoids,and the observation group was treated with ursodeoxycholic acid capsules.Both groups were treated for 6 months.The clinical effect,liver fibrosis indicators,immune function and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the liver fibrosis indicators and immune function indicators of the observation group were lower than those of the control group(P<0.05).No obvious adverse reactions was found in the two groups during treatment.Conclusions Ursodeoxycholic acid capsules combined with glucocorticoids has significant effect in the treatment of AIH patients,which can improve the liver fibrosis indicators,promote the recovery of liver function,and enhance the immune function,with higher safety in clinical application.

关 键 词：自身免疫性肝炎 熊去氧胆酸胶囊 糖皮质激素 肝纤维化 免疫功能 

分 类 号：R575.1[医药卫生—消化系统]